MA09-hRPE ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
301黄斑ジストロフィー4

301. 黄斑ジストロフィー


臨床試験数 : 45 薬物数 : 46 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01625559
(ClinicalTrials.gov)
September 201218/6/2012Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)Stargardt's Macular DystrophyBiological: MA09-hRPECHABiotech CO., LtdNULLActive, not recruiting20 YearsN/ABoth3Phase 1Korea, Republic of
2NCT02445612
(ClinicalTrials.gov)
July 11, 201213/5/2015Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy PatientsLong Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)Stargardt's Macular DystrophyBiological: MA09-hRPEAstellas Institute for Regenerative MedicineNULLCompleted18 YearsN/AAll13Phase 1/2United States
3NCT01469832
(ClinicalTrials.gov)
December 13, 20118/11/2011Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)Stargardt's Macular DystrophyBiological: MA09-hRPEAstellas Institute for Regenerative MedicineNULLCompleted18 YearsN/AAll12Phase 1/Phase 2United Kingdom
4NCT01345006
(ClinicalTrials.gov)
June 16, 201128/4/2011Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular DystrophyA Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)Stargardt's Macular DystrophyBiological: MA09-hRPEAstellas Institute for Regenerative MedicineNULLCompleted18 YearsN/AAll13Phase 1/Phase 2United States